Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TEL-AVIV, Israel, Sept. 01, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
TEL-AVIV, Israel, Aug. 31, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted A...
-
TEL-AVIV, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple...
-
RedHill maintains a strong and debt-free balance sheet with $47.7 million in cash at the end of the second quarter, allowing the Company to continue to diligently execute its three ongoing Phase III...
-
RedHill has received a Notice of Allowance for an additional U.S. patent covering RHB-105, expected to be valid until 2034 once grantedThe planned confirmatory Phase III study with RHB-105 for the...
-
TEL-AVIV, Israel, July 19, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
TEL-AVIV, Israel, July 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
RedHill and its co-development partner, IntelGenx, have signed a definitive agreement with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORT™ in...